We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00498667
Recruitment Status : Withdrawn
First Posted : July 10, 2007
Last Update Posted : May 6, 2015
Sponsor:
Information provided by (Responsible Party):

July 8, 2007
July 10, 2007
May 6, 2015
December 2006
December 2009   (Final data collection date for primary outcome measure)
progression free survival [ Time Frame: 5 years ]
Not Provided
Complete list of historical versions of study NCT00498667 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma
A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Retention:   None Retained
Description:
no biopsies are to be retained
Probability Sample
all patients with agressive non hodgkin lymphoma who had interim pet/ct during therapy
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
Not Provided
PET/CT
all patients with aggressive lymphoma who had a baseline and interim pet/ct study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
December 2014
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • aggressive non-Hodgkin lymphoma b cells
  • age 18-70
  • bilirubin less then 2
  • creatinine less then 2
  • Pet/CT performed post 2 cycles

Exclusion Criteria:

  • no PET/CT post 2 cycles performed
  • bilirubin >2
  • creatinine more then 2
  • HIV positivity
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00498667
cc-NHL2615_CTIL
No
Not Provided
Not Provided
e_dann, Rambam Health Care Campus
Rambam Health Care Campus
Not Provided
Principal Investigator: Eldad J Dann, MD RAMBAM health care campus,Rappaport faculty of medicine Technion Israel Technical institute
Rambam Health Care Campus
May 2015